Role of Inflammatory Diseases in Hypertension

被引：24

作者：

Bartoloni E. ^{[1
]}

Alunno A. ^{[1
]}

Valentini V. ^{[1
]}

Luccioli F. ^{[1
]}

Valentini E. ^{[1
]}

La Paglia G. ^{[1
]}

Bistoni O. ^{[1
]}

Gerli R. ^{[1
]}

机构：

[1] Rheumatology Unit, Department of Medicine, University of Perugia, Perugia

来源：

High Blood Pressure & Cardiovascular Prevention | 2017年 / 24卷 / 4期

关键词：

Cardiovascular risk; Chronic inflammatory diseases; Hypertension;

D O I：

10.1007/s40292-017-0214-3

中图分类号：

学科分类号：

摘要：

Chronic inflammatory diseases (CID) are characterized by an increased risk of cardiovascular (CV) morbidity and mortality. Several mechanisms, including early acceleration of subclinical atherosclerotic damage, inflammatory markers and immune system deregulation factors, have been demonstrated to strictly interplay for development and progression of atherosclerosis. Moreover, traditional CV risk factors are likely to explain at least some of the excess of CV risk in these patients. Among traditional CV risk factors, compelling evidence suggests a higher incidence and prevalence of hypertension in patients with CID in comparison to the general population. Moreover, hypertension represents an important predictor of CV events in these patients. Pathogenic mechanisms underlying the rise of blood pressure in CID are multifactorial and still poorly investigated. Indeed, multiple disease-related factors may affect blood pressure control in these patients and hypertension may affect disease prognosis and increase CV risk. Better knowledge of the complex interplay between hypertension and CID will be important to elucidate pathogenic mechanisms and to improve CV outcome in these patients. Aim of this review is to highlight available evidence on the relationship between hypertension and CID and to elucidate the multiple factors that may affect blood pressure control in these disorders. © 2017, Springer International Publishing AG Switzerland.

引用

页码：353 / 361

页数：8

共 78 条

[1]

Laurent S., Boutouyrie P., The structural factor of hypertension. Large and small artery alterations, Circ Res, 116, pp. 1007-1021, (2015)

[2]

Coffman T.M., Under pressure: the search for the essential mechanisms of hypertension, Nat Med, 17, pp. 1402-1409, (2011)

[3]

Anders H.J., Baumann M., Tripepi G., Mallamaci F., Immunity in arterial hypertension: associations or causalities?, Nephrol Dial Transplant, 30, pp. 1959-1964, (2015)

[4]

Wenzel U., Turner J.E., Krebs C., Kurts C., Harrison D.G., Ehmke H., Immune mechanisms in arterial hypertension, J Am Soc Nephrol, 27, pp. 677-686, (2016)

[5]

Bartoloni E., Shoenfeld Y., Gerli R., Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin, Arthritis Care Res, 63, pp. 178-183, (2011)

[6]

Symmons D.P., Gabriel S.E., Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE, Nat Rev Rheumatol, 7, pp. 399-408, (2011)

[7]

Agca R., Heslinga S.C., van Halm V.P., Nurmohamed M.T., Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders, Heart, 102, pp. 790-795, (2016)

[8]

Panoulas V.F., Douglas K.M., Milionis H.J., Stavropoulos-Kalinglou A., Nightngale P., Kita M.D., Tselios A.L., Et al., Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis, Rheumatology, 46, pp. 1477-1482, (2007)

[9]

Chung C.P., Oeser A., Solus J.F., Avalos I., Gebretsadik T., Shintani A., Raggi P., Et al., Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis, Atherosclerosis, 196, pp. 756-763, (2008)

[10]

Muller R., Kull M., Polluste K., Aart A., Eglit T., Lember M., Kallikorm R., The metabolic profile in early rheumatoid arthritis: a high prevalence of metabolic obesity, Rheumatol Int, 37, pp. 21-27, (2017)

← 1 2 3 4 5 6 7 8 →